Description

PT-141 — Bremelanotide

PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide and melanocortin receptor agonist. The active pharmaceutical ingredient is approved by the FDA under the brand name Vyleesi for hypoactive sexual desire disorder. PT-141 acts on melanocortin receptors MC1R, MC3R, and MC4R in preclinical models. It has been the subject of research examining the central nervous system melanocortin pathway and its interaction with sexual function, inflammation, and neuroprotection.

Specifications

• CAS Number: 189691-06-3
• Molecular Weight: 1025.2 Da
• Amino Acids: 7
• Form: Lyophilized Powder
• Purity: ≥99% — Vanguard Laboratory Verified
• Storage: -20°C Lyophilized / 4°C Reconstituted
• Volume: 3ml

Testing and Verification

Every batch independently tested by Vanguard Laboratory — ISO/IEC 17025:2017 accredited, A2LA Certificate #6377.01.

For Research Use Only — Not For Human Consumption. This product is intended exclusively for laboratory and in-vitro scientific research purposes. It has not been evaluated by the FDA for safety or efficacy in humans or animals.